Brind.

Strong results from Plasma and Blood Center drove performance, leading to Mizuho reducing its price target, while FICO was noted as an alternative investment.

3 reports, 2 independent Updated Aug 23
Gone quiet Reached 2 outlets in its first 24 hours
Reports
3
Developments
3
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Strong results from Plasma and Blood Center drove performance, leading to Mizuho reducing its price target, while FICO was noted as an alternative investment.

Who's involved

What this event is mainly about
HaemoneticsFICO

How it developed

Newest first. Tap a step to see who reported it.
  1. Haemonetics/Plasma strong results drive performance; FICO mentioned as alternative investment.1 source
  2. Haemonetics CEO leads company while Mizuho inquires about plasma share gains.1 source
  3. CEO highlighted core product focus.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Insider MonkeyMizuho Reduces PT on Haemonetics Corporation (HAE) Following Fiscal Q1 2025 Results Haemonetics Corporation (NYSE:HAE) is one of the 13 Oversold Value Stocks to Invest in Now. An operating theatre wi
  • StockStoryThe Top 5 Analyst Questions From Haemonetics’s Q2 Earnings Call Haemonetics’ second quarter results were met with a significant negative market reaction, reflecting concerns about declining revenue d
  • StockStoryHAE Q2 Deep Dive: Margin Expansion Amid Revenue Decline and Product Execution Challenges Blood products company Haemonetics (NYSE:HAE). beat Wall Street’s revenue expectations in Q2 CY2025, but sales